RGD-conjugated mesoporous silica-encapsulated gold nanorods enhance the sensitization of triple-negative breast cancer to megavoltage radiation therapy.
Multifunctional nanoprobes have great potential as effective radiosensitizers and drug carriers. RGD-modified gold nanorods could increase the uptake of nanoparticles via receptor-mediated endocytosis in integrin alphaV beta3-overexpressing breast cancer cells, which could enhance the effects of radiation on tumor cells, leading to further radiosensitization. The purpose of our study was to demonstrate that RGD-conjugated mesoporous silica-encapsulated gold nanorods significantly enhanced the sensitization of triple-negative breast cancer to megavoltage energy. The results indicated that RGD-conjugated mesoporous silica-encapsulated gold nanorod multifunctional nanoprobes could achieve radiosensitization in vitro and in vivo, which suggests the potential translation of this nanotechnology to clinical applications in tumor-targeting and selective therapy.
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China; Department of Radiation Oncology, 6th People's Hospital of Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Ning
N
Zhao
Department of Radiation Oncology, 6th People's Hospital of Shanghai Jiao Tong University, Shanghai, People's Republic of China; Med-X Research Institute and School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Zhangru
Z
Yang
Department of Radiation Oncology, 6th People's Hospital of Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Bingxin
B
Li
Department of Radiation Oncology, 6th People's Hospital of Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Jin
J
Meng
Department of Radiation Oncology, 6th People's Hospital of Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Zeliang
Z
Shi
Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Ping
P
Li
Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Shen
S
Fu
D000818:Animals; D017209:Apoptosis / Q000187:drug effects / Q000528:radiation effects; D015153:Blotting, Western; D002453:Cell Cycle / Q000187:drug effects / Q000528:radiation effects; D049109:Cell Proliferation / Q000187:drug effects / Q000528:radiation effects; D004337:Drug Carriers / Q000737:chemistry*; D005260:Female; D005434:Flow Cytometry; D006046:Gold / Q000008:administration & dosage / Q000737:chemistry*; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D043942:Nanotubes / Q000737:chemistry*; D009842:Oligopeptides / Q000737:chemistry*; D011838:Radiation-Sensitizing Agents / Q000737:chemistry / Q000494:pharmacology*; D012822:Silicon Dioxide / Q000737:chemistry*; D064726:Triple Negative Breast Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy*; D014407:Tumor Cells, Cultured; D023041:Xenograft Model Antitumor Assays
D004337:Drug Carriers; D009842:Oligopeptides; D011838:Radiation-Sensitizing Agents; D006046:Gold; D012822:Silicon Dioxide; C047981:arginyl-glycyl-aspartic acid
Arg-Gly-Asp peptides; gold nanorods; integrin alphaV beta3; megavoltage radiation therapy; triple-negative breast cancer